- Home
- / Immunovant
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Immunovant financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$29.9
2024-10-29
Market Capitalization
$4.4 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| General and administrative expense | 18.2M | 39.5M | 54.2M | 48.0M | 57.3M | 77.2M |
| Operating expense total | 66.1M | 108.1M | 156.0M | 208.3M | 270.2M | 438.2M |
| Interest expense | 625.0K | 7.6M | 24.9M | |||
| Pre tax profit | (66.3M) | (107.8M) | (156.8M) | (211.0M) | (258.8M) | (412.9M) |
| Income tax expense | 97.0K | (400.0K) | (84.0K) | 9.0K | 567.0K | 891.0K |
| Net Income | (66.4M) | (107.4M) | (156.7M) | (211.0M) | (259.3M) | (413.8M) |
| EPS | (1.4) | (1.7) | (1.9) | (2.7) |